ＩＢＤに対する最新の内科治療　　治療成績と効果発現機序に関するｒｅｖｉｅｗ　　２．クローン病に対する抗ＴＮＦ－α抗体療法：最新の知見を基に

• 高添 正和

  社会保険中央総合病院内科

• 田中 寅雄

  社会保険中央総合病院内科

• 岩垂 純一

  社会保険中央総合病院大腸肛門病センター

書誌事項

タイトル別名

• Targeted therapy for Crohn's disease (CD)-monoclonal antibody anti-TNF-.ALPHA. therapy

抄録

Conventional treatments for CD are nonspecific, and target the suppression or regulation of inflammatory responses ; however, the mechanism of action is not well understood. These treatments improve symptoms for the short term, but it is difficult to prevent post-inflammatory sequelae and avoid surgery. In recent years, the treatment of CD has been approaching a turning point : the use of biological products targeting cytokines causing mucosal inflammation, such as, the endogenous protein preparation anti-TNFα antibody (infliximab). The second targeting treatment is a specific inhibitor of the transcription activity of a specified gene (pathway for signal conversion), and it is in the process of development. However, these biological preparations are also limited in their effectiveness ; therefore, conventional treatments must be used in conjunction.<BR>In the treatment of CD, it is important to understand the cascade of mucosal inflammation based on the results of previous studies on genetics, immuno-regulation, signal transduction, intestinal microecology, host-microbial interactions, epithelial cell biology, tissue injury, and fibrogenesis.

収録刊行物

• 日本大腸肛門病学会雑誌

  日本大腸肛門病学会雑誌 56 (10), 841-848, 2003

  日本大腸肛門病学会

キーワード

• クローン病
• 抗TNF-α抗体
• 粘膜炎症カスケード

詳細情報

• CRID: 1390001204855877632
• NII論文ID: 10012437742
• NII書誌ID: AN00195100
• DOI: 10.3862/jcoloproctology.56.841
• ISSN: 18829619
• ISSN: 00471801
• Web Site: http://www.jstage.jst.go.jp/article/jcoloproctology1967/56/10/56_10_841/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2004099347
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可